Today analysts at N 1 Singer reiterated Vernalis Plc’s (LON:VER) shares as ‘Hold’ in a report released to investors.
According to N 1 Singers price target of 28 on the company’s stock this indicates the broker now believes there is an increase of 27.27% from Vernalis Plc’s current price of 22.
In the last year Vernalis Plc’s stock price has decreased by -56.55% from 50.63 to 22.
The number of Vernalis Plc shares in issue is 526,351,000 which have a current share price of 22 bringing Vernalis Plc’s market capitalisation to 115.80M GBp.
The 52 week high of shares in Vernalis Plc is 51.95 while the 52 week low for the company’s shares is 20. The businesses 50 day moving average is 24.55 and its 200 day moving average is 31.87.
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.